Nonfatal self-poisoning with LMW heparin and the use of antidote

Thrombosis Research

Volumn 126, Issue 5, 2010, Pages

  Bjornaas, Mari A ^a   Jacobsen, Eva M ^a,b   Jacobsen, Dag ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Antidote; Dalteparin; Poisoning

Indexed keywords

ANTIDOTE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; CITALOPRAM; DALTEPARIN; HEPARIN; LAMOTRIGINE; LOW MOLECULAR WEIGHT HEPARIN; PROMETHAZINE; PROTAMINE SULFATE; SALICYLIC ACID;

ADULT; ALCOHOL ABUSE; ANTICOAGULATION; BINDING AFFINITY; CARDIOPULMONARY BYPASS; CASE REPORT; CLINICAL EXAMINATION; DRUG EFFECT; FEMALE; GENE MUTATION; HEMOSTASIS; HUMAN; LETTER; PARTIAL THROMBOPLASTIN TIME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SELF POISONING; SUICIDE ATTEMPT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; FEMALE; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POISONING; PROTAMINES;

EID: 78149283096     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.08.026     Document Type: Letter

References (19)

1. M.A. Howland Antidotes in depth: Protamine N. Flomenbaum, L. Goldfrank, R.S. Hoffman, M.A. Howland, N. Lewin, L. Nelson, Goldfrank's Toxicological Emergencies 2006 McGraw-Hill New York 907 910
2. J. Holst, B. Lindblad, D. Bergqvist, K. Garre, H. Nielsen, and U. Hedner Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers Blood Coagul Fibrinolysis 5 1994 795 803
3. M.A. Crowther, L.R. Berry, P.T. Monagle, and A.K. Chan Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin Br J Haematol 116 2002 178 186
4. http://www.medicines.ie/medicine/12799/SPC/Protamine+sulphate+LEO+Pharma. Summary of Product Characteristics (SPC) for Protamine Sulphate. LEO Pharma. Accessed August 3, 2010.
5. http://www.medicines.org.uk/emc/medicine/9148. Summary of Product Characteristics (SPC) for Fragmin. The electronic Medicines Compendium (eMC). Accessed August 3, 2010.
6. Y. Schulz, K.-P. Larsch, J.-P. Weller, U. Gropper, F. Länger, and D. Breitmeier Suicid durch subkutane Masseninjektion niedermolekularen Heparins (Suicide by subcutaneous mass injection of low-molecular-weight heparin) Rechtsmedizin 19 2009 95 101
7. G. Waser, S. Kathriner, and W.A. Wuillemin Performance of the automated and rapid STA Liatest D-dimer on the STA-R analyzer Thromb Res 116 2005 165 170
8. C.J. Stockley, M.J. Reed, D.E. Newby, A.J. Coull, G.R. Clegg, and A.J. Gray The utility of routine D-dimer measurement in syncope Eur J Emerg Med 16 2009 256 260
9. http://www.interaksjoner.no. Drug Information Database (DRUID) - Legemiddelinformasjon for norske klinikere. Accessed March 30, 2010.
10. http://www.medicines.org.uk/emc/medicine/15313/SPC/Phenergan+Elixir. Summary of Product Characteristics (SPC) for Phenergan. The electronic Medicines Compendium (eMC). Accessed August 3, 2010.
11. J. Missliwetz, C. Korninger, and W. Denk Todesfall infolge Heparinüberdosierung (A fatality caused by heparin overdose) Z Rechtsmed 103 1989 147 153
12. J.T. Wiernikowski, A. Chan, and G. Lo Reversal of anti-thrombin activity using protamine sulfate. Experience in a neonate with a 10-fold overdose of enoxaparin Thromb Res 120 2007 303 305
13. M.K. Pugsley, V. Kalra, and S. Froebel-Wilson Protamine is a low molecular weight polycationic amine that produces actions on cardiac muscle Life Sci 72 2002 293 305
14. A.J. Velders, and C.R. Wildevuur Platelet damage by protamine and the protective effect of prostacyclin: an experimental study in dogs Ann Thorac Surg 42 1986 168 171
15. V.L. Ng Anticoagulation monitoring Clin Lab Med 29 2009 283 304
16. H. Bounameaux, and P. de Moerloose Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No J Thromb Haemost 2 2004 551 554
17. J. Harenberg Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes J Thromb Haemost 2 2004 547 550
18. J.N. Fiessinger Laboratory monitoring of low-molecular-weight heparin therapy J Thromb Haemost 2 2004 1007
19. C. Kearon Laboratory monitoring of low-molecular-weight heparin therapy J Thromb Haemost 2 2004 1006 1007